<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1099">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146843</url>
  </required_header>
  <id_info>
    <org_study_id>48347821.8.0000.5249</org_study_id>
    <nct_id>NCT05146843</nct_id>
  </id_info>
  <brief_title>The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients</brief_title>
  <official_title>The Impact of Chronic Mitochondrial Antioxidant (MitoQ) Supplementation on Cardiovascular Toxicity Induced by Doxorubicin-Based Adjuvant Chemotherapy in Breast Cancer Patients: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D'Or Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D'Or Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity&#xD;
      induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test the hypothesis that chronic MitoQ supplementation in breast cancer patients treated with&#xD;
      doxorubicin prevents:&#xD;
&#xD;
        1. increased mitochondrial oxidative stress;&#xD;
&#xD;
        2. the increase in cardiac markers (B-type natriuretic peptide and troponin I);&#xD;
&#xD;
        3. changes in left ventricular deformity (speckle tracking, strain) and reduction in LVEF;&#xD;
&#xD;
        4. endothelium-dependent dysfunction of peripheral vascular beds;&#xD;
&#xD;
        5. the increase in endothelial microvesicles;&#xD;
&#xD;
        6. the increase in material stiffness;&#xD;
&#xD;
        7. the elevation of central blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">December 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical, randomized, double-blind, placebo-controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of the left ventricular deformity and reduction in left ventricular ejection fraction</measure>
    <time_frame>3 Months</time_frame>
    <description>Cardiac function changes (Strain and Simpson's monoplanar)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic markers of oxidative stress</measure>
    <time_frame>3 Months</time_frame>
    <description>Mitochondrial oxidative stress; Cardiac markers (B-type natriuretic peptide and troponin I);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-dependent dysfunction of peripheral vascular beds</measure>
    <time_frame>3 Months</time_frame>
    <description>changes in the endothelium-dependent function of peripheral vascular beds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>3 Months</time_frame>
    <description>Increase in the arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central blood pressure</measure>
    <time_frame>3 Months</time_frame>
    <description>Alterations on the central blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical capacity</measure>
    <time_frame>3 Months</time_frame>
    <description>Reduction in the peak oxygen uptake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Mitoquinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MitoQ, 20 mg per day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 20 mg per day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoquinone</intervention_name>
    <description>Mitoquinone pill, 20 mg/day</description>
    <arm_group_label>Mitoquinone</arm_group_label>
    <other_name>MitoQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill, 20 mg/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years old, diagnosed with breast cancer (ductal, lobular and mixed&#xD;
             carcinoma), in stage 1-3, with indication for the adjuvant AC-T therapeutic scheme,&#xD;
             doxorubicin (60 mg/m2) plus cyclophosphamide, will be considered eligible for the&#xD;
             study (600 mg/m2) in the regimen of 1 cycle every 21 days, followed by weekly taxane&#xD;
             for 12 cycles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with metastasis, severe lymphedema, renal failure, acute myocardial&#xD;
             infarction, heart failure, stroke and chronic liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Kluser Sales, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>D'Or Institute of Research and Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allan Kluser Sales, PhD</last_name>
    <phone>55+21996482036</phone>
    <email>allan.sales@idor.org</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>D'Or Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Allan Robson Kluser Sales</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Doxorrubicin</keyword>
  <keyword>Mitoquinone</keyword>
  <keyword>Cardiotoxicity</keyword>
  <keyword>Peripheral vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

